The global regulatory landscape for psychedelic drugs
Jessica R. Riggleman
Open Access Government April 12, 2023 DOI: 10.56367/oag-38-10778 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Law |
| Key findings | The global regulation of psychedelic drugs is complex and varies by country and drug, but most countries classify them as controlled substances with differing legal and medical restrictions on use, possession, and distribution, with Schedule I classification a central focus. |
Abstract
Jessica Riggleman, Owner of Raeco, LLC, examines the global regulatory landscape for psychedelic drugs, with a particular focus on Schedule I classification. Depending on the country and specific drug, the global regulatory landscape for psychedelic drugs is complex and variable. Generally, most countries regulate psychedelic drugs as controlled substances, with varying degrees of legal and medical restrictions on their use, possession, and distribution.